Medline Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $1.16B | $1.16B | $234.0M |
| Depreciation & Amortization | $1.01B | $977.0M | $951.0M |
| Depreciation | $307.0M | $292.0M | $289.0M |
| Amortization | $704.0M | $685.0M | $662.0M |
| Stock-Based Compensation | $76.0M | $61.0M | $78.0M |
| Net Cash from Operating Activities | $1.74B | $1.77B | $1.69B |
| Investing Activities | |||
| Capital Expenditures | $447.0M | $354.0M | $275.0M |
| Business Acquisitions | $-6.0M | $1.13B | $16.0M |
| Net Cash from Investing Activities | $-474.0M | $-1.49B | $-312.0M |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | $33.0M | $20.0M | $0 |
| Net Cash from Financing Activities | $399.0M | $-1.61B | $-191.0M |
| Net Change in Cash | $1.69B | $-1.34B | $1.19B |
| Free Cash Flow | $1.30B | $1.42B | $1.41B |